Toward Multi-Center MR Brain Perfusion

描述（由申请人提供）：一种新的治疗方法似乎有望治疗最严重的脑癌——胶质母细胞瘤。监测这些抗血管生成疗法的机制将极大地帮助我们理解它们如何最好地用于患者，最近的数据表明，使用基于钆的方法用MRI测量脑灌注可能非常有用，特别是作为成像生物标志物。然而，没有一种单一的采集或分析方法在可变场强或跨供应商平台上进行过测试。我们建议开发采集和分析方法，这些方法将在不同的领域优势和供应商平台上兼容，并量化采集和分析的差异。我们将首先研究志愿者，以了解现场制造商和场强变异性。然后，我们将研究新诊断的胶质母细胞瘤患者，他们正在接受抗血管生成药物的治疗。预计这种方法将提高灌注MRI作为一种潜在的成像生物标志物的可靠性，并为大规模、多中心的试验铺平道路，从而标准化灌注MRI在测量肿瘤对抗血管生成治疗反应方面的实施。

DESCRIPTION (provided by applicant): A new treatment appears hopeful for the most severe form of brain cancer, glioblastoma. Monitoring these antiangiogenic therapies mechanistically would greatly aid our understanding of how they might best be used in patients, and recent data suggest that measurement of brain perfusion with MRI using gadolinium-based approaches could be very useful, particularly as an imaging biomarker. However, no single methodology for acquisition or analysis has been tested in at variable field strengths or across vendor platforms. We propose to develop acquisition and analysis methods that will be compatible across field strengths and vendor platforms and quantify the differences in acquisition and analysis. We will first study volunteers to understand the on-site manufacturer and field strength variability. We will then study patients with newly diagnosed glioblastoma who are undergoing treatment with anti-angiogenic agents. It is expected that such an approach will improve the reliability of perfusion MRI as a potential imaging biomarker, and pave the way for a large-scale, multi-center trial that could standardize the implementation of perfusion MRI in measuring tumor response to anti-angiogenic therapies.